Pitolisant, the only FDA-approved histamine H3 receptor antagonist for narcolepsy, has demonstrated promise in alleviating symptoms such as EDS and REM sleep disturbances (49). This evidence concerns the gene HRH3 and Ehlers-Danlos syndrome.